← All trials
NCT01136850
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2009
- Primary completion
- Dec 1, 2012
- Completion date
- Jan 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 2793
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of MelbourneLead sponsor
- University of MelbourneOverall official - principal investigator
- Papua New Guinea Institute of Medical ResearchCollaborator
- Walter and Eliza Hall Institute of Medical ResearchCollaborator
- University of BarcelonaCollaborator
- University of MelbourneReponsible party - principal investigator
- University of Western AustraliaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.